
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo is benefiting from accelerating top-line momentum, with fiscal Q2 2026 revenue of $11.7 million, up 21% year over year and above both estimates and guidance, while EPS of $(0.09) also outperformed expectations. The fundamental outlook is strengthened by stronger unit sales, a lower reimbursement pipeline and manageable backlog that still supports future conversions, plus raised 2026 revenue guidance to $45 million to $47 million and Q3 guidance of $11.5 million to $12.0 million. Long-term growth is further supported by the March 2024 Medicare Part B ruling, which materially expands the reimbursable market for MyoPro and is driving rapid growth in U.S. O&P revenue, which rose 100% in 2025 and 130% in Q2.
Bears say
Myomo is facing a weakening liquidity profile, with cash declining to $14 million from $16 million at the end of March while debt rose to $12 million from $11 million, suggesting less financial flexibility. Its prior balance sheet also showed deterioration, with cash down to $16 million from $18 million at the end of December, reinforcing concerns that the company may need to fund operations and commercialization under tighter conditions. Beyond the balance sheet, the business remains exposed to reimbursement uncertainty, regulatory and commercialization risks, and shifting healthcare priorities, all of which could pressure execution and investor confidence.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares